Skb Sebia

[Chiquita Palafox]

Basedin Mainz, Germany, ORGENTEC Diagnostika is a world market leader in the development, production, and marketing of diagnostic tests to detect autoimmune and blood diagnostics and treatment-associated monitoring. Clinical areas include: inflammatory rheumatic diseases, thrombosis diagnostics, blood diagnostics for the serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and diabetes diagnostics.

Since partnering with Water Street in 2014, ORGENTEC has expanded its services and capabilities significantly. The company acquired Arotec in 2014 and Corgenix in 2015 to become a leading global provider of proprietary diagnostic solutions focused on improving patient outcomes and reducing the cost of care. A scientifically driven organization, ORGENTEC today offers a comprehensive and high-quality menu of diagnostic products and services for diseases that are difficult to diagnose.

About Sebia Founded in 1967, Sebia is a world leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic testing. Its systems analyze proteins in order to screen and monitor various diseases and conditions; primarily oncology (multiple myeloma), metabolic disorders such as diabetes and also hemoglobinopathy and rare pathologies. The company is headquartered in Lisses, France, and operates across more than 120 countries. Sebia is owned by CVC Capital Partners, Tthys invest and Caisse des Dpt du Qubec. For more information, visit www.sebia.com

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Sebia is currently the only global partner covering the process of M-protein testing from initial detection to MRD and is committed to developing other liquid biopsy tests such as Circulating Tumor Cells (CTC) and new biomarkers.

About multiple myeloma

Multiple myeloma is the second most common blood cancer in the world, affecting more than 170,000 people worldwide. Multiple myeloma is the cancer of plasma cells characterized by the clonal expansion of plasma cells that predominantly reside in the bone marrow. Each year over 32,000 new cases are diagnosed in the United States, and almost 13,000 patients die of the disease. Patients with multiple myeloma continue to relapse over time, making it a difficult to treat and incurable malignancy.

About M-inSight

M-inSight is a Laboratory Developed Test (LDT) validated for clinical use, offered by Corgenix, a Sebia Group company, a CAP-accredited CLIA-licensed clinical laboratory. Patients suffering from multiple myeloma can now have access to M-inSight. Pharma companies developing and commercializing drugs in multiple myeloma can also benefit from this innovative assay to get deeper insights in their drug development and clinical trials.

www.minsight-mrd.com

About Corgenix

Corgenix is a CAP/CLIA accredited laboratory based in Colorado, USA. Founded in 1990 and part of the Sebia group, it is specialized in clinical trial management and physician-ordered patient testing.

The company also has CDMO capabilities catering to clients in the biotechnology and pharmaceutical industry, cancer centers and academic laboratories.

www.corgenix.com

About Sebia

Founded in 1967, Sebia is a world-leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in vitro diagnostic testing. Its systems analyze proteins in order to screen and monitor various diseases and conditions; primarily oncology (multiple myeloma), metabolic disorders, hemoglobinopathy, rare diseases and more recently autoimmunity. Sebia is offering the largest range of analytical solutions in diagnosis and monitoring of multiple myeloma, including serum and urine protein(s) electrophoresis (SPE/UPE) for screening and identification (Immunotyping / Immunofixation), measurement of FLC and follow-up monoclonal antibody therapy with HYDRASHIFT portfolio.

www.sebia.com

3a8082e126